

July 27, 2009



Pressure BioSciences, Inc. to Present At the Jesup & Lamont 2009 Growth Stock & National Sales Conference

SOUTH EASTON, Mass., July 27, 2009 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI") today announced that it has been invited to present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference at the Waldorf Astoria Boca Beach Club on July 30th, 2009 in Boca Raton, Florida. Mr. Richard T. Schumacher, PBI President and CEO, will give a corporate overview at 4:00 pm (EDT).

Jesup's annual conference provides its clients a distinctive forum in which to visit with and hear presentations from unique growth companies in the life sciences, healthcare, aerospace and transportation industries. The conference commences with Life Science industry and investor panels on Wednesday July 29th with Company presentations on Thursday July 30th, followed by Investment Products presentations on August 1st and 2nd. Last year's conference brought together hundreds of institutional and retail investors in an intimate format.

Former FDA Commissioner Dr. Lester M. Crawford D.V.M., Ph.D., will be the keynote speaker for this year's event. More information can be found online at www.jesuplamontconferences.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 U.S. and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts in the development and sale of PCT-enhanced enzymatic digestion products (instruments and consumables) designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, histology, forensics, and counter-bioterror applications.

Forward-Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and

results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website <http://www.pressurebiosciences.com>

CONTACT: Pressure BioSciences, Inc.
Investor Contacts:
Richard T. Schumacher, President & CEO
R. Wayne Fritzsche, Chairman
(508) 230-1828